Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-345820
Filing Date
2026-08-12
Accepted
2026-08-12 08:15:13
Documents
79
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ck0001540171-20260630.htm   iXBRL 10-Q 3265753
2 EX-31.1 ck0001540171-ex31_1.htm EX-31.1 17562
3 EX-31.2 ck0001540171-ex31_2.htm EX-31.2 17301
4 EX-32.1 ck0001540171-ex32_1.htm EX-32.1 9832
5 EX-32.2 ck0001540171-ex32_2.htm EX-32.2 9854
  Complete submission text file 0001193125-26-345820.txt   11059039

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001540171-20260630.xsd EX-101.SCH 1156897
82 EXTRACTED XBRL INSTANCE DOCUMENT ck0001540171-20260630_htm.xml XML 1975266
Mailing Address 105 W FIRST ST. BOSTON MA 02127
Business Address 105 W FIRST ST. BOSTON MA 02127 (206) 707-0340
Avalyn Pharma Inc. (Filer) CIK: 0001540171 (see all company filings)

EIN.: 452463191 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43251 | Film No.: 261265409
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)